Physician profile
Michael A Dankovich
NPI 1013913326
$5,733.69
in general payments reported to CMS, 2019-2025
23 companies · $1,253 in 2025
The $1,253 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $288 · 2020: $783 · 2021: $504 · 2022: $498 · 2023: $1,158 · 2024: $1,249 · 2025: $1,253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,659.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,282.78 | 2022-2025 | Xiidra, Miebo, Infuse |
| Sun Pharmaceutical Industries INC. | $605.83 | 2019-2025 | Cequa |
| Abbvie INC. | $528.37 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Novartis Pharmaceuticals Corporation | $507.33 | 2019-2023 | |
| Alcon Vision LLC | $499.63 | 2019-2025 | Precision7, Rocklatan, Total30 |
| Allergan, INC. | $411.52 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $395.69 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $376.40 | 2019-2021 | |
| Oyster Point Pharma, INC. | $309.22 | 2022-2025 | Tyrvaya |
| Horizon Therapeutics Plc | $143.93 | 2022-2023 | Tepezza |
| Astellas Pharma US INC | $130.89 | 2023 | |
| Rxsight INC | $110.37 | 2024 | Rxsight Light Delivery Device (Ldd), Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Thea Pharma INC. | $88.63 | 2023-2024 | Iyuzeh |
| Aerie Pharmaceuticals, INC. | $66.36 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $62.75 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $46.30 | 2020-2024 | |
| Coopervision INC. | $39.24 | 2022-2023 | Myday Contact Lens |
| Biotissue Holdings INC. | $33.98 | 2024 | |
| Janssen Pharmaceuticals, INC | $24.36 | 2023 | Acuvue |
| Maculogix, INC. | $20.12 | 2019 | |
| Dompe US, INC. | $18.43 | 2025 | Oxervate |
| Eyevance Pharmaceuticals LLC | $17.34 | 2023 | Tobradex St |
| Harrow Eye, LLC | $14.22 | 2024 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dankovich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.